Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Some pharmacologic/mechanism statements are label-consistent, but the provided excerpts do not contain key label sections (e.g., indications, full dosage, adverse reactions beyond hepatotoxicity details, contraindications, boxed warnings, drug interactions). Several claims (including omissions about missing dosing/side effects) cannot be validated against the supplied label content.
Category Scores
Accurate Statements
Veozah (fezolinetant) is a prescription medicine.
Supported by general label context is not directly evidenced in the provided excerpts; however, the label excerpts provided do not contradict this statement.
Fezolinetant is an NK3 receptor antagonist.
Section 1 notes (active ingredient description): “45 mg oral tablets (NK3 receptor antagonist).”
Fezolinetant works by blocking the neurokinin 3 (NK3) receptor.
Section 1 notes describe fezolinetant as an NK3 receptor antagonist.
Blocking NK3 signaling reduces the hot-flash signal.
Not explicitly present in the provided label excerpts; supported only indirectly by the NK3 antagonist description.
Unsupported Statements
Veozah is used to treat moderate to severe hot flashes associated with menopause.
The provided label excerpts do not include the Indications section text.
Blocking NK3 signaling reduces the hot-flash signal.
The provided excerpts supplied focus on hepatotoxicity/monitoring and do not describe the mechanism-to-symptom effect.
By blocking NK3 signaling, fezolinetant reduces hot-flash frequency and severity in people with menopausal hot flashes.
Not stated in the supplied excerpts; no efficacy/endpoint language is included.
The provided information does not include dosing or administration details for Veozah.
The provided excerpts include dosing/administration: “Take a single 45 mg VEOZAH tablet orally once daily with or without food.”
The provided information does not list Veozah's side effects.
The provided excerpts include adverse reaction information related to hepatotoxicity (clinical trials elevations and postmarketing serious hepatotoxicity).
Contradictions
Low
AI Statement
The provided information does not include dosing or administration details for Veozah.
Label Reference
Dosage and Administration 2.1: “Take a single 45 mg VEOZAH tablet orally once daily with or without food.”
Low
AI Statement
The provided information does not list Veozah's side effects.
Label Reference
Adverse Reactions 6.1 and 6.2 and Warnings/Precautions 5.1: includes elevated transaminases and postmarketing serious drug-induced hepatotoxicity with associated symptoms.
Important Omissions
Exact label wording/requirements for indications (including severity and menopausal hot flashes linkage) are not evaluated because the Indications section is not present in the provided excerpts.
Importance:
Moderate
Contraindications, boxed warnings, drug interactions, and complete adverse reaction profiles are not assessable because the supplied excerpts do not include those sections.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The response includes a couple of incorrect assertions about missing label information (dosing and side effects). While these are not direct dosing instructions, they could mislead users about what the label contains. The pharmacologic class/mechanism is only partially supported by the provided excerpts, and key safety sections beyond hepatotoxicity/monitoring are not evaluated.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Several claims cannot be supported by the supplied label excerpts (indication/efficacy/clinical mechanism), and two claims about absence of dosing/side effects are contradicted by the provided dosing and adverse reaction excerpts.
Suggested Improvement
Remove/qualify claims not present in the provided label text (Indications and efficacy/clinical mechanism-to-symptom statements). Do not state that dosing or side effects are absent when the excerpts explicitly provide dosing instructions and adverse reaction information related to hepatotoxicity/monitoring.